0000000000590892

AUTHOR

Christoph Pöttgen

showing 7 related works from this author

Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice

2003

Abstract Purpose The effect of recombinant human erythropoietin (rhEPO) on the radiosensitivity of human tumor xenografts growing in anemic and nonanemic nude mice was studied. Methods and materials Anemia was induced by total body irradiation ([TBI], 2 × 4 Gy) of mice before tumor implantation into the subcutis of the hind leg. The development of anemia was prevented by rhEPO (750 U/kg s.c.) given 3 times weekly starting 2 weeks before TBI. Fourteen days after fractionated TBI (tumor volume of approx. 40 mm 3 ), single-dose irradiation of the tumor with varying doses was performed so that in full dose–response relationship for the probability of tumor cure was obtained. Results Radiation-i…

Cancer ResearchPathologymedicine.medical_specialtyAnemiamedicine.medical_treatmentTransplantation HeterologousDrug Evaluation PreclinicalUrologyMice NudeHindlimbRadiation ToleranceHemoglobinsMicemedicineAnimalsHumansRadiology Nuclear Medicine and imagingRadiosensitivityddc:610ErythropoietinRadiationbusiness.industryAnemiaSarcomaHypoxia (medical)Total body irradiationmedicine.diseaseCell HypoxiaRecombinant ProteinsRadiation therapyRadiation Injuries ExperimentalOncologyErythropoietinDose Fractionation RadiationHemoglobinmedicine.symptombusinessNeoplasm TransplantationWhole-Body Irradiationmedicine.drug
researchProduct

Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic …

2020

Purpose: We aimed to compare treatment results in and outside of a randomized trial and to confirm factors influencing outcome in a large retrospective cohort of nonmetastatic medulloblastoma treated in Austria, Switzerland and Germany. Methods and Materials: Patients with nonmetastatic medulloblastoma (n = 382) aged 4 to 21 years and primary neurosurgical resection between 2001 and 2011 were assessed. Between 2001 and 2006, 176 of these patients (46.1%) were included in the randomized HIT SIOP PNET 4 trial. From 2001 to 2011 an additional 206 patients were registered to the HIT 2000 study center and underwent the identical central review program. Three different radiation therapy protocols…

Oncologymedicine.medical_specialtyMultivariate analysismedicine.medical_treatmentMedizinTreatment results030218 nuclear medicine & medical imaginglaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMedicineRadiology Nuclear Medicine and imagingScientific Articleddc:610MedulloblastomaUnivariate analysisddc:618business.industryHazard ratioRetrospective cohort studymedicine.diseaseRadiation therapyOncology030220 oncology & carcinogenesisbusinessAdvances in Radiation Oncology
researchProduct

Tumour oxygenation during fractionated radiotherapy--comparison with size-matched controls.

1999

The effect of fractionated irradiation on the oxygenation status of experimental tumours was investigated using polarographic assessment of the pO2 distribution. Since an improvement in tumour oxygenation could simply be the result of tumour shrinkage, a comparison of pO2 readings of untreated size-matched control tumours was performed. Irradiation was carried out using 6 fractions of 6 Gy applied within 11 days. A comparison of polarographic pO2 data with size-matched untreated tumours revealed a significant improvement in oxygenation after the irradiation. The median pO2 was 0.9+/-0.1 mm Hg for unirradiated tumours at a volume of 180 mm3, while the corresponding data for irradiated tumour…

inorganic chemicalsFractionated radiotherapymedicine.medical_treatmentTransplantation HeterologousMice NudeMiceOxygen ConsumptionMedicineAnimalsHumansRadiology Nuclear Medicine and imagingddc:610Oxygen pressurebusiness.industryDose-Response Relationship RadiationHematologyGeneral MedicineOxygenationrespiratory systemTumour oxygenationSpecific Pathogen-Free OrganismsRadiation therapyOncologyEstablished cell lineFractionated irradiationNeurofibrosarcomacardiovascular systemDose Fractionation RadiationbusinessNuclear medicineNeoplasm Transplantationcirculatory and respiratory physiologyActa oncologica (Stockholm, Sweden)
researchProduct

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Smal…

2015

Purpose Concurrent chemoradiotherapy with or without surgery are options for stage IIIA(N2) non–small-cell lung cancer. Our previous phase II study had shown the efficacy of induction chemotherapy followed by chemoradiotherapy and surgery in patients with IIIA(N2) disease and with selected IIIB disease. Here, we compared surgery with definitive chemoradiotherapy in resectable stage III disease after induction. Patients and Methods Patients with pathologically proven IIIA(N2) and selected patients with IIIB disease that had medical/functional operability received induction chemotherapy, which consisted of three cycles of cisplatin 50 mg/m2 on days 1 and 8 and paclitaxel 175 mg/m2 on day 1 ev…

AdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsPaclitaxelmedicine.medical_treatmentMedizinPhases of clinical researchVinblastineVinorelbineDrug Administration SchedulePneumonectomyCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPneumonectomyLung cancerAgedNeoplasm Stagingbusiness.industryDose fractionationInduction chemotherapyVinorelbineChemoradiotherapyInduction ChemotherapyMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTreatment OutcomeOncologyFemaleDose Fractionation RadiationCisplatinbusinessChemoradiotherapymedicine.drugJournal of Clinical Oncology
researchProduct

Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice

2001

Purpose: The effect of recombinant human erythropoietin (Epo) on the radiosensitivity of human tumour xenografts growing in anaemic nude mice was studied. Methods and materials: Anaemia was induced by total body irradiation (TBI) of mice prior to tumour transplantation. The development of anaemia was prevented by Epo (1000 U/kg s.c.) given 3 times weekly starting 2 weeks prior to TBI (5 Gy). Epo treatment did not influence the growth rate of the tumours, which were transplanted into the subcutis of the hind leg of mice. Thirteen days after TBI (tumour volume of approx. 40 mm3), a single-dose irradiation (12 Gy) of the tumour was performed resulting in a growth delay with subsequent regrowth…

Radiation-Sensitizing AgentsCancer ResearchPathologymedicine.medical_specialtyRatónAnemiaMice NudeBiologyMicehemic and lymphatic diseasesInternal medicinemedicineAnimalsHumansRadiosensitivityddc:610ErythropoietinHematologyAnemiaNeoplasms ExperimentalGeneral MedicineTotal body irradiationHypoxia (medical)medicine.diseaseCombined Modality TherapyXenograft Model Antitumor AssaysCell HypoxiaRecombinant ProteinsTransplantationOncologyErythropoietinCancer researchmedicine.symptomCell Divisionmedicine.drug
researchProduct

MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY – A REPORT …

2020

Abstract PURPOSE To evaluate prognostic factors and impact of participation in a randomized trial in non-metastatic medulloblastoma. METHODS AND PATIENTS 382 patients with non-metastatic medulloblastoma aged 4–21 years with primary neurosurgical resections between 2001 and 2011 were enrolled into the HIT 2000 trial and centrally reviewed. Between 2001 and 2006, 176 of these patients participated in the randomized trial HIT-SIOP PNET 4. Three different radiotherapy protocols were applied. Molecular subgroup was available for 157 patients. RESULTS Median follow-up was 6.35 [0.09–13.86] years. The 5-year progression-free (PFS) and overall survival (OS) rates were 80.3 % ± 2.1 % and 86.5 % ± 1.…

OncologyMedulloblastomaCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedicine.diseaseRadiation therapyOncologyInternal medicineMedulloblastoma (Clinical)AcademicSubjects/MED00300Non metastaticMedicineAcademicSubjects/MED00310Neurology (clinical)businessNeuro-Oncology
researchProduct

Prophylactic cranial irradiation in stage IV small cell lung cancer

2019

Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodology.Results: The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age…

OncologyMaleESTRO; Expert opinion; IASLC; PCI; Small cell lung cancer; Stage IV; Hematology; Oncology; Radiology Nuclear Medicine and ImagingLung Neoplasmsmedicine.medical_treatmentMedizin030218 nuclear medicine & medical imaging0302 clinical medicineQUALITY-OF-LIFENuclear Medicine and ImagingESTRO610 Medicine & healthStage IVHematologyBrain NeoplasmsRadiation OncologistsPCIHematologyMiddle AgedProgression-Free SurvivalExpert opinion030220 oncology & carcinogenesisFemaleTRIALNon small cellRadiologyAdultmedicine.medical_specialtyDecision Making03 medical and health sciencesInternal medicinemedicineHumansIASLCRadiology Nuclear Medicine and imagingLung cancerAgedNeoplasm StagingChemotherapySmall cell lung cancerbusiness.industryPatient Selectionmedicine.diseaseONCOLOGYSmall Cell Lung CarcinomaYoung ageConventional PCIProphylactic cranial irradiationCranial IrradiationbusinessStage ivRadiotherapy and Oncology
researchProduct